ABSTRACT
Apramycin, an aminocyclitol aminoglycoside, was rapidly bactericidal against Acinetobacter baumannii. In a neutropenic murine thigh infection model, treatment-associated A. baumannii CFU reductions of >4 log10 per thigh were observed for all exposures for which area under the curve (AUC)/MIC ratio was >50 and maximum concentration of drug in serum (Cmax)/MIC was ≈10 or higher. Based on these findings, we suggest that apramycin deserves further preclinical exploration as a repurposed therapeutic for multidrug-resistant Gram-negative pathogens, including A. baumannii.
FOOTNOTES
- Received 19 December 2017.
- Returned for modification 8 January 2018.
- Accepted 11 January 2018.
- Accepted manuscript posted online 16 January 2018.
Supplemental material for this article may be found at https://doi.org/10.1128/AAC.02585-17.
- Copyright © 2018 American Society for Microbiology.